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Objectives. The purpose of this study was to determine the risk
of epicardial lead failure during long-term follow-up and its mode
of presentation.
Background. Despite the high prevalence of epicardial lead–
based implantable cardioverter-defibrillators, their long-term
performance is unknown, and appropriate follow-up has not been
established.
Methods. The study group comprised all patients in whom an
epicardial lead system was implanted at the Mayo Clinic between
October 31, 1984 and November 3, 1994. The number of lead
fractures and leads with fluid within the insulation and the mode
of presentation were determined retrospectively by review of
patient visits, radiographs of lead systems and data derived from
formal lead testing.
Results. At 4 years, the survival rate free of lead malfunction,
using formal lead testing, for 160 Medtronic epicardial patches
(models 6897 and 6921) was 72% compared with 92.5% for the 179
Cardiac Pacemaker, Inc. (CPI) patches (models 0040 and 0041)
(p 5 0.01). In addition, five Medtronic patches in three patients
had fluid within the lead insulation but no obvious fracture. No
CPI patches had fluid identified within the leads. Of 330
Medtronic epicardial pace/sense leads (model 6917), the 4-year
survival rate free of lead malfunction as assessed by lead testing
was 96%. In all, 19 presentations of lead malfunction were found
in 17 patients (2 patients had more than one lead fracture at
different times). In 11 (58%) of these presentations, the patients
were asymptomatic despite the presence of obvious lead fracture.
Conclusions. Epicardial lead malfunction is common on long-
term follow-up, and some leads have a failure rate of 28% at 4
years. Many patients with fractured leads remain asymptomatic,
despite involvement of multiple leads in some cases. Therefore,
consideration should be given to regular periodic lead testing in
addition to routine X-ray examination, as asymptomatic lead
malfunction can present with normal chest X-ray findings.
(J Am Coll Cardiol 1998;31:616–22)
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Because of the effectiveness of the implantable cardioverter-
defibrillator (ICD) in preventing sudden death (1,2), as many
as 25,000 persons each year in the United States are candidates
for the devices under currently accepted criteria (3,4). Al-
though consistent implantation of nonthoracotomy lead sys-
tems is now possible (5), many patients still have epicardial
lead systems although little is known about the long-term
durability of such systems or the appropriate follow-up of those
patients. Therefore, in the present study we attempted to
determine the long-term performance of epicardial lead sys-
tems, the clinical mode of presentation of epicardial lead
malfunction and the utility of screening examinations, radio-
graphs and formal lead testing in detecting epicardial lead
system malfunction. On the basis of our findings, we propose
guidelines for the long-term follow-up of patients with an ICD.
Methods
Patients. The study group comprised all 171 patients in
whom an epicardial ICD lead system was implanted at the
Mayo Clinic between October 31, 1984 and November 3, 1994.
Characteristics of the study patients, including the number of
previous and concomitant surgical procedures, are summa-
rized in Table 1.
Lead systems. Epicardial lead systems from two manufac-
turers, Medtronic, Inc. and Cardiac Pacemakers, Inc. (CPI),
were used exclusively. Medtronic epicardial patch models 6897
(n 5 64) and 6921 (n 5 96) were analyzed. These are identical
except for the connector pin, which is 6.5 mm in model 6897
and 3.2 mm in model 6921. Because of the similarity of these
two models, data from each lead system were combined for the
purposes of analysis. (Data supporting combining these two
leads for analysis are presented under Results.) The CPI
patches (n 5 179) analyzed were models 0040 and 0041.
Almost all of the epicardial pace/sense leads implanted during
the study period were Medtronic model 6917. Only four CPI
pace/sense leads (model 4312) were implanted; none of these
had evidence of malfunction and all four were excluded from
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further analysis. All patches use silicone as the insulator,
platinum iridium as the conductor material and stainless steel
as the manifold (mandrel) connecting the lead body to the
patch.
Device implantation. Surgeons at our institution first im-
planted epicardial lead systems using CPI patches in 1984.
Implantation of Medtronic patches began in 1989. Initially
implanted pulse generators included AID B models (n 5 16),
CPI Ventak models 1500 through 1600 (n 5 52), which did not
have noninvasive testing capability (40%), and PRx I model
1705 (n 5 16), Medtronic PCD models 7216 and 7217 (n 5 86)
and Ventritex model V-100C (n 5 1), which did have nonin-
vasive testing capability (60%). All devices were implanted
with the patient in the postabsorptive state and under general
anesthesia. In general, surgical implantation was performed
with use of a left thoracotomy approach unless concomitant
surgery, such as coronary artery bypass graft surgery (CABG)
or valve surgery, was planned, when a median sternotomy
approach was used.
Data collection. Data reviewed included the patients’ med-
ical records, our ICD data base, data obtained from elective
lead testing during scheduled follow-up and radiographs ob-
tained after implantation and during follow-up. Each X-ray
film obtained after lead implantation in all patients was
reviewed retrospectively by one of us (M.S.S.). All X-ray films
of patients with known lead malfunction were reviewed sepa-
rately, and a particular effort was made to attempt to identify
any X-ray evidence of lead abnormality. For the patients
without known lead abnormalities, the same investigator
(M.S.S.) carefully reviewed each X-ray film in a systematic
fashion, following each lead through its entire course. All
X-ray films from each patient were subsequently rereviewed
with experts from the lead divisions of the respective manu-
facturers in an attempt to identify any factors that may have
contributed to lead failure. Thus, the films were all overread in
an unblinded manner. In addition, X-ray films from all patients
were reviewed separately, in a blinded manner, by an experi-
enced electrophysiologist to determine the sensitivity and
specificity of X-ray data when used alone in the diagnosis of
lead problems.
Follow-up. After device implantation and before discharge,
all patients underwent comprehensive lead testing that in-
cluded pacing threshold, sensed electrogram measurement (in
devices with this capability) and arrhythmia induction. Pacing
and sensing function were assessed every 3 months. Addition-
ally, our routine follow-up recommendation was to repeat
arrhythmia induction testing at 3 and 12 months after implan-
tation, yearly thereafter (in ICDs capable of programmed
stimulation), at the time of pulse generator replacement or
whenever clinically indicated. A posteroanterior (PA) and
lateral chest radiograph was performed before discharge, after
implantation and every 6 months thereafter according to our
protocol. An abdominal radiograph was frequently, though not
consistently, obtained if the entire lead system was not visible
on the chest X-ray film. The mean number of X-ray films
obtained in each patient during the follow-up period was 15
(range 1 to 113). At 3, 6 and 12 months after implantation, the
proportion of patients who had follow-up X-ray data available
was 91%, 85% and 93%, respectively. At 2 and 4 years the
proportion of patients who had follow-up X-ray data available
was 72% and 71%, respectively.
Definitions. Lead malfunction was said to occur if one or
more of the following was present: 1) lead conductor fracture
evident on X-ray film; 2) lead conductor fracture evident on
inspection of the lead at the time of operation; 3) evidence of
lead malfunction at electrical testing including a) pacing
threshold .10 V at 0.5-ms pulse width, b) impedance .2,000
ohms for pacing or .200 ohms for shock delivery, or c)
documented random oversensing (i.e., not related to cardiac
events) resulting in lead abandonment.
Fluid (i.e., serum or blood) was sometimes visualized within
the lead body. Leads with such fluid were routinely abandoned,
at times without being tested. The clinical implications of fluid
Abbreviations and Acronyms
CABG 5 coronary artery bypass graft surgery
ICD 5 implantable cardioverter-defibrillator
PA 5 posteroanterior
Table 1. Characteristics of 171 Patients With an Implanted
Cardioverter-Defibrillator
Age (yr) 62 6 14
Men 135 (79%)
LVEF (%) 33 6 14
Cardiac disease
CAD 101
DCM 21
CAD 1 DCM 22
HCM 7
Congenital/valvular disease 5
Primary electrical disease 15
Prior thoracic surgical procedure
CABG alone 59
CABG plus AVR 1
MVR alone 2
AVR alone 3
Concomitant thoracic surgical procedure
CABG alone 28
CABG plus
MVR 8
AVR 1
Aneurysmectomy 3
Surgical approach
Median sternotomy 44
Left thoracotomy 125
Subxiphoid 2
Data are presented as mean value 6 SD or number (%) of patients. AVR 5
aortic valve replacement; CABG 5 coronary artery bypass graft surgery; CAD 5
coronary artery disease; DCM 5 dilated cardiomyopathy; HCM 5 hypertrophic
cardiomyopathy; LVEF 5 left ventricular ejection fraction; MVR 5 mitral valve
replacement.
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within the lead body are unclear (see Discussion). If fluid was
identified and none of the preceding observations defining lead
malfunction were present, the finding was defined as a fluid
event. Fluid events were analyzed separately and were not
combined with lead malfunction data except where specified.
Statistical analysis. Three separate analyses of lead sur-
vival were performed. Method 1 assumed that implanted leads
were functioning in surviving patients at follow-up unless a
lead malfunction was specifically documented. Thus, lead
survival was the interval from implantation to the last
follow-up visit or contact (at which point the data were
censored) or the interval from implantation to documented
failure. Method 2 determined lead survival as the interval from
implantation to the most recent radiograph demonstrating an
intact system (for those leads without malfunction) or as the
interval from implantation to the documented failure. Because
some patients had not had a recent X-ray film at the time of
this analysis, follow-up times were shorter when this method
was used. In Method 3 the most rigorous method, lead survival
was the interval from implantation to the most recent electrical
test documenting normal lead functioning or the interval from
implantation to the documented failure. In all analyses, data
for all leads free of failure were censored at the last follow-up
end point. From these three end points (last patient follow-up,
intact system on X-ray film and normal lead function on
electrical testing), lead survival was determined by using the
Kaplan-Meier method (6). A log-rank test was used to deter-
mine whether a difference between survival of different patches
existed. Results are expressed as mean value 6 SE.
Results
Patients and implanted leads. One hundred seventy-one
patients underwent initial implantation of an epicardial lead
system (Table 1). Seventy-five of these patients received 160
Medtronic patches (model 6897 in 64 and model 6921 in 96).
The other 96 patients received 179 CPI model 0040 and 0041
patches. In most cases Medtronic 6917 pace/sense epicardial
screw-in leads were implanted (330 leads in 163 patients). Only
four CPI model 4312 pace/sense leads were implanted; be-
cause none of these were found to have fractured or to have
fluid within the insulation, they were excluded from further
analysis. The mean follow-up time was 4.57 6 0.08 years
(maximal 5.4) and 3.39 6 0.09 years (maximal 8.9) for the
Medtronic and the CPI patch, respectively, and 8.34 6 0.11
years for the Medtronic 6917 pace/sense lead.
Lead malfunction and fluid events. Among the 179 CPI
patches, three fractures (2%) were found in two patients (2%).
These fractures occurred at 3.5 and 3.4 years after implanta-
tion. No fluid was found within the insulation of any CPI lead
during visual inspection at pulse generator replacement oper-
ations.
Among the 160 Medtronic patches, 12 lead malfunctions
(7.5%) were found in nine patients (12%); 10 (16%) of the
involved patches were model 6897 and 2 (2%) were model
6921. These malfunctions occurred a mean of 4.43 6 0.12 years
(range 2.52 to 4.85) after implantation. In addition, five (8%)
of the Medtronic 6897 patch leads in three patients were found
to have fluid within the lead insulation with no documented
evidence of fracture of the lead. Two of these patients also had
fractures in other patches and are, therefore, also included in
the lead malfunction group. No fluid events were identified in
the 6921 patches. Among the 330 Medtronic 6917 pace/sense
leads, seven fractures (2%) were found in seven patients (4%).
No fluid events were observed in these leads.
Lead survival after implantation. Figures 1 to 3 show for
each lead survival curves based on end points derived from
1) patient follow-up data, 2) X-ray data, and 3) data obtained
from electrical lead testing. Figure 1A depicts lead survival
free from lead malfunction as assessed by data from Medtronic
6897 and 6921 patch leads combined. The mean freedom from
lead malfunction of these patches at 4 years, as assessed by
using all three end points, was 80.2 6 6.3%. Figure 1B shows
survival free of lead malfunction and fluid events for both
Medtronic patches combined. At 4 years of follow-up, 23% of
leads had evidence of malfunction (including fracture and fluid
events) as assessed with use of patient follow-up data, and 30%
had evidence of malfunction as assessed by lead testing. When
data derived retrospectively from X-ray films were analyzed,
the mean failure rate of the Medtronic patches at 4 years was
27%. Figure 1C illustrates freedom from malfunction of each
of the Medtronic 6897 and 6921 patches when analyzed
separately. No significant difference between the lead survival
rates of models 6897 and 6921 was found within the shorter
follow-up period of model 6921.
Lead survival for CPI model 0040 and 0041 patches is
shown in Figure 2. At 4 years the fracture-free lead survival
rate as assessed by patient follow-up data was 96.2 6 2.1%.
This rate was significantly higher than that found for the
Medtronic patch at 4 years (p , 0.01). No fluid events were
observed in the CPI 0040 or 0041 patches. Figure 3 illustrates
freedom from malfunction of the Medtronic 6917 pace/sense
lead. The marked decrease in survival at the 8-year follow-up
period follows a single event occurring in a small group of
patients at this late time after implantation. Overall, for this
lead, mean freedom from malfunction at 4 years as assessed by
all three data end points was 96.7 6 1.6%.
Mode of presentation of lead malfunction (Table 2). In
total, 17 patients with 22 lead malfunctions and 5 fluid events
presented on 19 occasions (2 patients had lead problems on
more than one occasion). Seven patients with fractured pace/
sense electrodes presented with oversensing, which was the
most common mode of presentation. An isolated fluid event
without evidence of concomitant lead fracture occurred in one
patient and was discovered because of failure of pacing at the
highest voltage during pace/sense lead testing. One patient,
with a fracture in each of two patches, presented with unsuc-
cessful defibrillation of spontaneous in-hospital ventricular
fibrillation and required external cardioversion. In 11 (58%) of
the 19 presentations, the patients were asymptomatic. These 11
patients comprised three patients whose condition was diag-
nosed after failed defibrillation; three whose diagnosis was
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made after lack of pacing output during routine electrophysi-
ologic lead testing and follow-up, including one patient with an
isolated fluid event; 4 patients whose lead malfunction was
diagnosed during routine pulse generator replacement for
battery depletion; and one patient in whom a previously
unsuspected diagnosis of lead malfunction was made on X-ray
evidence alone. Careful retrospective review of all relevant
radiographs demonstrated that evidence of lead fracture was
apparent in only 68% of the 19 presentations. No false positive
“fractures” were detected. In the blinded review, sensitivity of
X-ray data when used alone to diagnose lead fracture was 71%.
When all lead malfunction events were included in the analysis
(lead fracture and fluid events causing lead problems), the
sensitivity of X-ray data was 62%. The specificity of X-ray
diagnosis was 100% as there were no false positive findings.
Six patients died suddenly during the follow-up period. No
lead fractures were identified in any of these patients. In all
except one of these six patients, the ICD system was implanted
before 1990, and interrogations are not available to indicate
whether a failed shock might have been the cause of death.
The maximal interval between the occurrence of sudden death
Figure 1. Kaplan-Meier lead survival curves based on end points
derived from patient (Pt) follow-up (F-U) data, X-ray data and lead
testing data. On the ordinate is cumulative survival of these leads,
plotted against time in years after implantation. Each curve represents
data from each of the three end points. The numbers below the curve
represent the number of leads at risk of malfunction, using each end
point, for each year of follow-up. A, Fracture-free survival of
Medtronic model 6897 and 6921 patch leads. B, Fracture-free and fluid
event-free survival combined for Medtronic 6897 and 6921 patch leads.
C, Survival of Medtronic model 6897 and 6921 patch leads shown
separately. The similarity of the curves reflects the similarity of the
leads, which are identical except for the size of the connector pin.
Release of model 6897 lead preceded that of model 6921 lead; thus,
follow-up of the model 6897 lead is longer.
Figure 2. Fracture-free survival of the CPI patch electrodes. Axes and
abbreviations as in Figure 1.
Figure 3. Fracture-free survival of the Medtronic model 6917 pace/
sense lead. Axes and abbreviations as in Figure 1.
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and follow-up in these six patients was 3 months for X-ray
examination and 6 months for lead testing.
Site of fracture. All leads were intact without marked
bending at the site of eventual fracture, on review of the first
X-ray film after implantation. The fracture site of Medtronic
patch and pace/sense leads is shown in Figure 4. The exact
fracture site was not visible in two epicardial pace/sense leads
(model 6917), and was unavailable for one lead. No specific
fracture site was found predominantly in either lead, suggest-
ing the importance of complete visualization of the entire lead
system on all follow-up X-ray films.
Discussion
This study provides information on the long-term perfor-
mance of two epicardial defibrillation lead systems that ac-
count for the vast majority of epicardial leads already im-
planted worldwide. We found that epicardial lead malfunction
during long-term follow-up is more common than previously
reported (1). Specifically, lead malfunction was identified in 22
leads (12 Medtronic model 6897 and 6921 patches [7.5%], 3
CPI patches [2%] and 7 Medtronic pace/sense leads [2%]). In
addition, 5 Medtronic 6897 patch leads (8%) had fluid within
the lead insulation on direct inspection. However, no fluid was
observed within the lead insulation of the CPI patches or the
Medtronic 6921 patches or 6917 pace/sense leads. Of particu-
lar importance was the finding that most lead failures occurred
.2 years after implantation (mean 4.43 6 0.12 years
[Medtronic patches] and 3.39 6 0.02 years [CPI patches] after
implantation as assessed from data derived from lead testing
[Fig. 1 to 3]). This finding argues for continued close late
follow-up of all patients with an epicardial lead system.
Most patients with lead malfunction were asymptomatic,
despite multiple lead fractures in some cases, (Fig. 5). We
could not identify a patient characteristic predictive of multiple
lead fractures. One patient had been involved in a motor
vehicle accident 9 months before presentation with fractures of
two CPI patches. Although in many cases fractures could be
identified after careful retrospective review of the chest or
abdominal radiograph, in which the entire lead system was
visible, evidence of a fracture could be quite subtle (Fig. 5). In
almost one third of presentations no fracture was visible. Fluid
within the lead insulation could be detected only by visual
inspection of the lead at operation.
The high failure rate of epicardial leads in our patients may
be a result of several factors, including surgical trauma at the
time of implantation, mechanical forces related to cardiac
motion or chemical factors causing lead degradation. The
possibility that lead malfunction was related to surgical tech-
nique is unlikely, as surgeons at our institution first began
implantation of epicardial defibrillators in 1984 by using CPI
lead systems. Medtronic patches were first implanted in 1989.
Therefore, any learning curve related to device implantation
would most likely have coincided with implantation of the CPI
lead systems, which was not the case in our experience.
Similarly, it is possible that the increased tunneling required
during a lateral thoracotomy approach, used most frequently
by the surgeons performing implantation in this study, may
have contributed to lead complications. If this was the case,
similar rates of complications might be expected for CPI and
Medtronic leads and would be expected to occur sooner after
implantation than they did. Furthermore, review of the X-ray
fracture sites on earlier radiographs with normal findings did
not reveal any acute bend of the involved lead that might have
led to undue strain and fracture. Such a mechanism is believed
to be responsible for a least some fractures reported previously
(7–11). Fractures were not observed in this study before 2 years
of follow-up, again supporting the hypothesis that the observed
lead problems were unlikely to be due to surgical technique or
to lead trauma during implantation (7).
The role played by other physiochemical factors is poorly
defined. A definitely fractured lead will not function normally,
and it should be replaced. Less clear is the management
approach when fluid is discovered within the lead insulation
(defined as a fluid event in this analysis) but the lead is
functionally normal under full testing. The insulation of both
CPI and Medtronic leads is manufactured from silicone which,
under normal circumstances, is permeable to serous fluid.
However, larger elements such as cells or solid material are not
Figure 4. Fracture site for the Medtronic patch (models 6897 and
6921) and pace/sense (model 6917) electrodes (drawing not to scale).
Numbers above the arrows represent the number of lead malfunctions
found at each site. The exact fracture site of the Medtronic model 6917
pace/sense lead could not be identified in two cases and was not
available in one case.
Table 2. Mode of Clinical Presentation
All
Presentations
Presentations
With Abnormal
X-Ray Film
Oversensing 7 4
Failed conversion of spontaneous VF 1 1
Routine lead testing
Lack of defibrillation 3 3
No pacing output 3 1
Pulse generator replacement 4 3
X-ray film alone 1 1
Total 19 13
Data presented are number of presentations. VF 5 ventricular fibrillation.
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expected to permeate silicone, and the presence of such
elements within the lead insulation suggests a breach of the
insulation or of vulnerable parts of the lead system such as
joints or connector ends. Therefore, the presence of blood
within the lead insulation suggests an insulation breach. More-
over, although it is unclear whether a small breach can affect
electrical performance, persistence of the causative factor or
factors may lead to propagation of the defect and to subse-
quent lead dysfunction. This sequence of events has been
described for both epicardial (12) and endocardial (7,13) leads.
Differences in the design of the CPI and Medtronic leads may
in part explain the absence of fluid in the CPI leads. Figure 6,
which presents a cross section of each lead, shows that the
space surrounding the coil is larger in the Medtronic patch. In
addition, the insulation of the Medtronic lead is thinner, and
the inner portion of the CPI lead insulation is red, which could
prevent visualization of fluid. The electrical performance of
lead systems that have fluid within the lead insulation is
uncertain. However, in the five instances in our study in which
fluid was found within the lead insulation, two of the three
affected patients had concomitant fractures of other leads,
raising the concern that subclinical fractures may occur that
cannot be identified on chest X-ray examination. Thus, the
presence of an insulation breach in any lead system should
alert the treating physician to the possibility of other system-
related problems. Prophylactic abandonment of a lead with
fluid within the insulation should be strongly considered.
In most cases, lead system malfunction is diagnosed be-
cause patients present with symptoms suggestive of lead prob-
lems. Our finding that epicardial pace/sense lead malfunction
presents most commonly with inappropriate ICD discharges
due to oversensing is in agreement with earlier studies (8,14).
Of greater importance is our finding that 11 of 19 lead
malfunction presentations were asymptomatic and detected
only by routine surveillance with X-ray examinations and
electrical lead testing; this observation suggests that the prev-
alence of clinically important epicardial lead system malfunc-
tion may be underestimated. Although no deaths were found
to be directly attributable to lead malfunction, one patient with
two patch fractures presented with unsuccessful defibrillation
of spontaneous ventricular fibrillation and required external
cardioversion. In addition, in three patients lead problems
were diagnosed after failure to defibrillate induced ventricular
fibrillation during lead testing. Such events further emphasize
the importance of routine follow-up for early detection of lead
malfunction.
Recommendations for follow-up. Formal recommenda-
tions for routine follow-up of patients with an ICD have not
been published by cardiology organizations. Some manufactur-
ers include in their product manuals the recommendation that
chest X-ray examinations be performed every 6 months. How-
ever, they acknowledge, and our informal polling confirms,
that most physicians do not follow this practice. We (15) have
previously published our approach to the follow-up of patients
with an ICD. The findings of the present study argue for the
use of periodic X-ray examinations and electrophysiologic
assessment of lead integrity and function. Our data show that
neither assessment alone detects all lead abnormalities. Newer
ICDs may be able to assess defibrillation lead impedance
without shocks. With such devices it should be possible to
assess defibrillation lead integrity without arrhythmia induc-
Figure 5. Left: Lateral radiograph demonstrating
lead fractures close to anterior and inferior
Medtronic model 6897 patches (solid arrows) and
fractured helix displaced from adjacent Medtronic
model 6917 pace/sense lead (open arrow). Right,
Subtle fracture of mid-lead body of model 6897
patch seen on PA view.
Figure 6. Cross-sectional comparison of Medtronic model 6897 and
6921 patch leads and the CPI model 0040/0041 patch. Major design
differences include the size of the airspace around the coil, which is
larger in Medtronic model 6897 and 6921 patches, and the thickness of
the insulation used. All dimensions are in inches.
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tion. As lead fractures presented between 2 and .8 years after
implantation, routine continued follow-up is essential. One
approach would be to assess pacing and sensing thresholds,
check pacing lead impedance and review a routine radiograph
of the lead every 6 months and, in addition, perform arrhyth-
mia induction to test defibrillator lead function and impedance
annually. For patients with lead models demonstrating a high
failure rate, such as those described here, some physicians may
elect to offer prophylactic lead replacement with a nonthora-
cotomy system.
Limitation of the study. Lead malfunction rates may be
underestimated because some patients refuse electrophysi-
ologic testing at follow-up and because data on the function of
leads implanted in patients who died may be incomplete. In
addition, the fact that early devices were not capable of
providing enhanced diagnostic information may have reduced
the detection rate of lead malfunction, resulting in further
underestimation of the incidence of lead malfunction in our
study. However, the number of leads at risk detailed in the
Figures 1a and 2 shows that, at 4 years after implantation
electrophysiologic testing of lead systems was actually more
common in patients with CPI leads than in those with
Medtronic leads. This difference was predominantly due to
lead testing at ICD pulse generator replacement in the group
with CPI leads. Our initial analysis was based on a retrospec-
tive review of X-ray films that reflects a best case scenario in
the X-ray diagnosis of lead fracture. In routine clinical prac-
tice, however, the sensitivity of X-ray films may be lower, and
the incidence of false positive findings higher. We tried to
address these uncertainties by having an experienced electro-
physiologist conduct a blinded review of all X-ray data from all
patients in the study. This review found that the sensitivity of
X-ray data was 71% when they alone were used to diagnose
lead fracture, but it decreased to 62% when all malfunctioning
leads were included in this analysis because leads with fluid
within the insulation, but without a visible fracture, were
reported as normal. The latter rate of 62% may more closely
reflect the sensitivity of X-ray data in routine clinical practice.
Whether unrecognized lead malfunction was a factor in the six
sudden deaths that occurred during follow-up cannot be
determined. Moreover, sudden deaths due to lead malfunction
occurring in the early part of the study could have been
underestimated if some deaths were misclassified as “nonsud-
den” and attributed to other causes. The vast majority of
pace/sense leads used in this series were made by one manu-
facturer (Medtronic), and these results cannot necessarily be
extrapolated to other leads. The implications for nonthora-
cotomy leads are unknown. However, it should be noted that
the construction of the Medtronic subcutaneous patch is
similar to that of the Medtronic epicardial patches.
Conclusions. Lead malfunction was common on long-term
follow-up of epicardial systems and occurred in close to 30% of
some leads at 4 years. In addition, fractures were most
frequently observed .2 years after implantation and were
identified in most cases in asymptomatic patients during
routine surveillance utilizing X-ray examinations and formal
lead testing. Taken together, these findings highlight the
importance of regular lead testing in patients with an epicar-
dial ICD.
ADDENDUM. Since acceptance of this report, we have dis-
covered three additional patients with lead fractures. Two
leads were Medtronic 6921 patches with fractures detected due
to ventricular tachycardia nonconversion and incidently noted
at pulse generator changeout occurring 4.4 and 5.6 years after
implantation, respectively. The other lead was a Medtronic
6917 pace/sense electrode discovered due to lack of pacing
capture occurring 3.2 years after implantation. All three lead
fractues were visible on X-ray films.
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